Cytosorbents (CTSO) Current Deferred Revenue (2013 - 2026)

Cytosorbents (CTSO) has reported Current Deferred Revenue for 9 consecutive years, with $1.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Current Deferred Revenue rose 215.51% year-over-year to $1.1 million; the trailing twelve-month figure through Jun 2026 stood at $1.1 million (up 215.51% YoY), and the FY2025 full-year result was $182000.0, down 69.46% from the prior year.
• Current Deferred Revenue improved to $1.1 million in Q2 2026 per CTSO's latest filing, from $34000.0 in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $1.5 million in Q4 2022 and bottomed at $34000.0 in Q1 2026.
• Historically, Current Deferred Revenue has averaged $684291.2 across 5 years, with a median of $546028.0 in 2025.
• The widest YoY moves for Current Deferred Revenue: up 215.51% in 2026, down 93.77% in 2026.
• Over 5 years, Current Deferred Revenue stood at $1.5 million in 2022, then fell by 8.96% to $1.4 million in 2023, then plunged by 56.84% to $596000.0 in 2024, then slumped by 69.46% to $182000.0 in 2025, then surged by 525.82% to $1.1 million in 2026.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $1.1 million, $34000.0, and $182000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.